These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22890586)

  • 1. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR).
    Součková L; Opatřilová R; Suk P; Čundrle I; Pavlík M; Zvoníček V; Hlinomaz O; Šrámek V
    Eur J Clin Pharmacol; 2013 Mar; 69(3):309-17. PubMed ID: 22890586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets.
    Zafar MU; Farkouh ME; Fuster V; Chesebro JH
    J Interv Cardiol; 2009 Aug; 22(4):385-9. PubMed ID: 19496900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of clopidogrel after administration of a high loading dose.
    Taubert D; Kastrati A; Harlfinger S; Gorchakova O; Lazar A; von Beckerath N; Schömig A; Schömig E
    Thromb Haemost; 2004 Aug; 92(2):311-6. PubMed ID: 15269827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
    Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
    von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
    Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs.
    Brainard BM; Kleine SA; Papich MG; Budsberg SC
    Am J Vet Res; 2010 Jul; 71(7):822-30. PubMed ID: 20594086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Frundi D; Stratz C; Valina CM; Bestehorn HP; Büttner HJ; Neumann FJ
    Thromb Haemost; 2008 Jan; 99(1):174-81. PubMed ID: 18217151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Burchardt P; Kruszyna L; Komosa A; Lesiak M; Główka F
    Clin Pharmacokinet; 2014 Feb; 53(2):155-64. PubMed ID: 24127209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
    Koh JS; Park Y; Tantry US; Ahn JH; Kang MG; Kim K; Jang JY; Park HW; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA; Jeong YH
    Platelets; 2017 Mar; 28(2):187-193. PubMed ID: 27560946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation.
    Seyfarth HJ; Koksch M; Roethig G; Rother T; Neugebauer A; Klein N; Pfeiffer D
    Am Heart J; 2002 Jan; 143(1):118-23. PubMed ID: 11773921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
    Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
    Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.